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1. Introduction  
Malignant melanoma is one of the most aggressive human cancers. Metastatic melanoma is 
highly resistant to genotoxic radiotherapy and chemotherapeutic treatments and patients have 
a median survival of under a year from diagnosis. As primary melanoma tumours can 
metastasise very early in tumour development (Chin et al., 2006), rapid diagnosis and curative 
surgery remain the best hopes for control of the disease. Early surgery that removes radial 
growth phase tumours that have not yet initiated vertical growth phase can be very effective 
and prevent further development. However, once the primary tumour has begun to invade the 
local epidermal and dermal environment treatment becomes much more complicated  
Why melanoma has such a high propensity to invade and metastasize is not well 
understood, but may be related to the developmental characteristics of the melanocyte 
lineage. Melanocytes derive from pluripotent neural crest cells as non-pigmented 
melanoblasts (Dupin et al., 2007; Dupin et al., 2006; Thomas and Erickson, 2008). During 
embryogenesis melanoblasts migrate via the dorso-lateral pathway to populate the basal 
layer of the epidermis and hair follicles, as well as a number of other sites including the 
inner ear and the heart (Yajima and Larue, 2008). The ability of transformed melanoma cells 
to rapidly invade and migrate away from the primary tumour perhaps reflects an inherent 
characteristic inherited from their embryonic state. 
Neural crest-derived cells are specified as melanoblasts by expression of MIcrophthalmia-
associated Transcription Factor (MITF), a basic helix-loop-helix transcription factor 
belonging to the MYC superfamily (Goding, 2000a; Goding, 2000b; Hemesath et al., 1994). 
The MITF locus encodes multiple isoforms generated by alternate splicing and use of 
internal promoters (Steingrimsson, 2008). The MITF-M isoform (hereafter designated simply 
as MITF) is produced specifically in the melanocyte lineage from an intronic promoter.  
MITF is required for melanoblast survival and differentiation of the retinal pigment 
epithelium (RPE) (Hou and Pavan, 2008; McGill et al., 2002). Consequently, MITF-null mice 
exhibit a white coat colour due to the loss of the melanocyte lineage and a small 
(microphthalmic) eye phenotype due to loss of the RPE (Hodgkinson et al., 1993; Hughes et 
al., 1993; Moore, 1995; Steingrimsson et al., 1994).  In humans, mutation of the MITF gene is 
responsible for Waardenburg syndrome type 2 (WS2) ((Tassabehji et al., 1994), a syndrome 
characterised by pigmentary defects and hearing loss highlighting the important role of the 
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melanocytes located in the inner ear. MITF is thus the master regulator specifying the 
identify and properties of the melanocyte lineage.  
It is now commonly accepted that exposure to solar UV irradiation and consequent DNA 
damage and mutation, especially during childhood, is the primary cause of most forms of 
melanoma (Bennett, 2008b). Melanoma can arise spontaneously, but often result from a 
stepwise process via accumulations of genetic changes leading first to formation of a benign 
naevus (mole) which can remain stable throughout the individual’s life. If one of the cells in 
the naevus then acquires additional mutations it can go on and form the malignant tumour.  
In contrast to many other tumours where a diversity of mutations can be found, melanoma 
formation is tightly associated with specific genetic changes. Activating mutations in BRAF 
especially the BRAFV600E mutation or mutations in NRAS are found in more than 60% of 
primary melanomas. (Bennett, 2008a). The resulting constitutive activation of the MAP 
kinase pathway promotes melanocyte proliferation, but cells with activated BRAF or NRAS 
eventually arrest proliferation in what is assumed to be a senescent state in the form of  
benign nevi. Escape from this arrested state involves additional mutations one of the most 
frequent of which is inactivation of the CDKN2A locus encoding the cyclin dependent 
kinase inhibitor p16INK4 (Larue and Beermann, 2007). This inactivation can occur through 
genetic lesions (Bennett, 2008a) or DNA hypermethylation and epigenetic silencing  
(Richards and Medrano, 2009; Rothhammer and Bosserhoff, 2007), or repression via 
activation of Wnt⁄beta-catenin signalling (Delmas et al., 2007).  The accumulation of these 
genetic and epigentic changes allows normal melanocytes to become immortal, escape 
senescence and go on to form malignant tumours.   
2. Phenotype switching versus genetic changes in tumour formation  
Following the genetic and epigentic changes described above, transformed melanoma cells 
enter the radial then the vertical growth phase where they acquire invasive properties. This 
is a critical event in tumour formation and two models have been put forward to account for 
how cells acquire the ability to invade neighbouring tissues, the lymphatic system and 
eventually form distant metastasis.  Cells in the primary tumour may acquire further genetic 
changes that promote invasion and metastasis. This would be an essentially irreversible 
genetic event that, unless additional mutations arise, would fix the properties of these cells. 
An alternate model that has been put forward in the case of melanoma is ‘phentoype 
switching’ which postulates that cells can reversibly switch from proliferative to invasive 
states (Hoek and Goding, 2010). This process involves a specific set of changes in gene 
expression and hence altered transcription factor activity and can take place dynamically 
within a population of cells in response to signals from the tumour microenvironment. 
The ‘phentoype switching’ model is based on two sets of observations. Firstly, analysis of 86 
cultured melanoma cell lines showed that they could be divided into two classes ; highly 
proliferative cells with low invasive potential and slowly dividing cells with much higher 
migratory and invasive potential (Hoek et al., 2008; Hoek et al., 2006). Gene expression 
profiling of these different cell types defined two distinct expression signatures in which a 
collection of 105 genes show the highest differential expression.  The invasive signature is 
characterised by up regulation of genes such as INHBA, COL5A1, and SERPINE1 that are 
involved in modifying the extracellular environment and are often known targets of TGFb 
signalling. In contrast, many of the proliferative signature genes are targets of Wnt 
signaling. Importantly however, a key feature of the two profiles revealed that invasive 
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phenotype cells exhibited low levels of MITF, while proliferative phenotype cells expressed 
high levels of MITF (Hoek et al., 2008; Hoek et al., 2006). These observations define at least 
two cell populations that differ in proliferative and invasive properties and are defined by 
distinct gene expression profiles including differential MITF expression.  
The second set of observations supporting this model are derived from experiments 
showing that when MITF high and MITF low cells are used to make xenografts, the 
resulting tumours comprise cell expressing both high and low MITF expression levels (Hoek 
et al., 2008). Hence, while the original cells were rather homogenous with respect to MITF 
expression, the resulting tumours are heterogenous.   The tumour microenvironment may  
therefore modify the gene expression profile allowing cells to switch from one state to the 
other in a dynamic way.  
This model is complicated by the observation that a low abundance subpopulation of cells 
that have strongly reduced MITF expression arise spontaneously in in vitro cultures of high-
MITF expressing cell lines (Cheli et al., 2011).  Depletion of these cells from the population 
leads to a strong reduction in tumour formation, whereas the purified low-MITF expressing 
population has high tumour formation potential and rapidly recovers higher MITF 
expression after subcutaneous injection. These observations confirm that cells can 
dynamically and even spontaneously switch their MITF expression and that low-MITF 
expressing cells have much higher tumour initiating capacity.  
These observations made from xenografted tumour cell lines have been confirmed in 
primary human tumours. Staining of primary tumours with antibodies against MITF 
showed a heterogenous pattern with cells that exhibited high levels of MITF and others that 
showed lower levels or were completely negative (Goodall et al., 2008). These results 
highlight the heterogeneity of cell populations within human tumours. This idea is 
reinforced by the observation that cells in human tumours with no MITF staining expressed 
high levels of a second transcription factor POU3F2 (also known as N-OCT3 or BRN2), 
while cells expressing high MITF showed low levels of POU3F2 (Goodall et al., 2008). Thus, 
these two transcription factors can act as markers for different cell populations within 
tumours. In an elegant approach, Pinner et al, (Pinner et al., 2009) used intravital imaging to 
follow the fate of xenografted human melanoma cells engineered to express green 
fluorescent protein under the control of the POU3F2 promoter. They were clearly able to 
show that the POU3F2 promoter was upregulated in motile cells and that these cells 
exhibited a de-differentiated phenotype with diminished pigmentation.  
Together the above results are consistent with the idea that cells expressing high levels of 
MITF are proliferative, but poorly motile and invasive, while those expressing low levels of 
MITF, but high levels of POU3F2 are highy motile and invasive and that this phenotype is 
acquired in a dynamic and reversible fashion in tumours. Spontaneous switching can also 
take place to a certain extent in cell culture, however, the low frequency of this event makes 
it a difficult process to follow. More recently however, Thurber et al (Thurber et al., 2011), 
showed that growth of high MITF expressing cells as non-adherent ‘melanospheres’ 
dramatically enhanced the frequency of low MITF/high POU3F2 expressing cells. Similarly, 
when we grew 501Mel cells expressing high levels of MITF in human embryonic stem cell 
medium under non-adherent conditions they readily form melanospheres, where we 
observe the appearance of a significant fraction of low MITF expressing cells in the spheres 
(Fig. 1). Thus, the change from monolayer to 3 dimensional culture in stem cells medium 
strongly influences MITF expression. Thurber et al, (Thurber et al., 2011) also showed using 
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siRNA silencing that POU3F2 was an activator and MITF a repressor of the Notch pathway. 
Loss of POU3F2-MITF signaling resulted in decreased capacity to form melanospheres and 
invasion through a collagen matrix. This in vitro model appears to recapitulate some of the 
characteristics of MITF and POU3F2 signaling seen in tumours and may therefore facilitate 
the identification of the signals and mechanisms that regulate melanoma cell heterogeneity 
in tumours.  
 
 
Fig. 1. Heterogenous MITF expression in 501Mel cells grown as melanospheres. The upper 
panels show phase contrast, MITF-labelling, nuclear Hoechst staining and the merge 
between the MITF and Hoechst signals of 501Mel cells grown as adherent monolayers under 
standard conditions. Almost all nuclei are stongly stained with MITF antibody.  In the lower 
panels, the cells were grown as melanospheres in human stem cell medium and a significant 
number of low-MITF expressing cells can now be seen. Representative low-MITF expressing 
cells are indicated by arrows. 
3. The MITF-POU3F2 axis in melanoma   
The results described above show that high levels of MITF promote melanoma cell 
proliferation and that MITF and POU3F2 show reciprocal levels of expression. Key 
questions are therefore how does MITF promote proliferation and how does POU3F2 
regulate MITF expression, proliferation and motility.  
i. POU3F2 an activator and a repressor of critical target genes in melanoma.  
POU (Pit, Oct1, Unc86) domain transcription factors play diverse functions in many 
physiological processes. The POU family factors have a bipartite DNA binding domain 
formed by the conserved POU-specific domain (POUs) and the POU homeodomain (POUh) 
that are joined by a linker region of variable length (Phillips and Luisi, 2000; Ryan and 
Rosenfeld, 1997). The POUs and POUh domains each comprise a helix-turn-helix structure 
of which the third helix recognises the DNA and provides sequence specificity (Cook and 
Sturm, 2008; Klemm et al., 1994).  
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POU3F2 and POU4F1 (BRN3) are involved in development of the central nervous system 
(Schonemann et al., 1998). Genetic studies in mice have demonstrated that POU3F2 is 
required for generation of specific neuronal lineages in the endocrine hypothalamus and the 
posterior pituitary gland (Nakai et al., 1995; Schonemann et al., 1995). POU3F2 also plays a 
role in the production and positioning of neocortical neurons (Sugitani et al., 2002). In 
addition to the nervous system, several studies have reported that POU3F2 is expressed in 
normal melanocytes and is upregulated in malignant melanoma cells where its expression is 
regulated by the Wnt/-catenin and activated BRAF signalling pathways (Cook et al., 2003; 
Eisen et al., 1995; Goodall et al., 2004a; Goodall et al., 2004b; Thomson et al., 1995). However, 
POU3F2 has not yet been selectively inactivated in the melanocyte lineage and genetic 
dissection of its role in normal melanocyte physiology and in melanoma will be a welcome 
and important addition to the field.  
POU3F2 directly represses MITF in melanoma cells through binding directly to the proximal 
internal promoter driving expression of the MITF-M isoform (Goodall et al., 2008). At least 3 
POU3F2 binding sites have been identified at the MITF-M locus, two in the proximal 
promoter region upstream of the transcription start site (TSS) and a third intronic site 
downstream of the TSS (Kobi et al., 2010). Wellbrock et al., (Wellbrock et al., 2008) have 
shown that in some melanoma cell types POU3F2 mediates the regulatory effect of the 
BRAFV600E mutation and induces MITF expression. As discussed above, this suggestion is at 
odds with what is observed in tumours and melanospheres. To reconcile what may appear 
to be contradictory observations, we have suggested that the POU3F2 binding to the site 
closest to the TATA element may repress MITF-M transcription through steric hindrance of 
the basal transcription machinery, for example TFIID, while POU3F2 may activate MITF-M 
transcription via binding to the other sites in the proximal promoter and downstream intron 
(Kobi et al., 2010). The ability to activate or repress may then be modulated by POU3F2 
concentration being able to efficiently compete with TFIID binding and repress MITF 
expression only at high concentrations. This model would reconcile the observation that 
POU3F2 is a transcription activator with the reciprocal MITF/POU3F2 expression seen in 
melanoma tumours (Goodall et al., 2008; Pinner et al., 2009). 
Another means by which POU3F2 and MITF may regulate each others expression is through 
control by miR-211. Boyle et al., (Boyle et al., 2011) have compared miRNA expression 
profiles and identified miR-211 as down-regulated in melanoma cell lines compared to 
normal melanocytes. MiR-211 is derived from the TRPM1 gene whose expression is directly 
regulated by MITF and it targets POU3F2 expression. Thus MITF driven expression of 
TRPM1/miR-211 provides a mechanism by which high MITF levels maintain low POU3F2 
levels. MiR-211 may also have other targets in melanoma. Levy et al., (Levy et al., 2010) have 
shown that  expression of miR-211 reduced migration and invasion in human melanomas 
with low miR-211 levels. They propose IGF2R, TGFBR2, and NFAT5 as miR-211 targets that 
mediate the phenotypic effects of its overexpression. In contrast, Mazar et al., (Mazar et al., 
2010) identified KCNMA1, encoding a calcium ion-regulated potassium channel protein, as 
a miR-211 target that influences melanoma cell aggressivity. MiR-211 has therefore many 
potential targets that influence melanoma cell properties. 
Can all of the effects of POU3F2 in melanoma be ascribed to its ability to repress MITF or 
does it regulate other target genes involved in melanoma development? Genome wide 
chromatin immunoprecipitation (ChIP) coupled to array hybridisation (ChIP-chip) profiling 
of POU3F2 promoter occupancy identified target genes that may be involved in modulating 
the properties of melanoma cells (Kobi et al., 2010). For example, siRNA-mediated 
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knockdown and transfection of reporter genes indicates that POU3F2 regulates expression 
of stem cell factor (Kit ligand, Kitl or Steel) via a cluster of 4 closely spaced binding sites 
located in the proximal promoter. Amplification and/or activating mutations of the KIT 
gene, encoding the KITL receptor, have been frequently found in mucosal, acral, and chronic 
sun-damaged melanomas (Garrido and Bastian, 2009), where it appears to promote 
melanoma development. The KITL/KIT pathway is also critical for promoting melanocyte 
migration during embryogenesis and hence may also be important in regulating the 
migratory/invasive properties of melanoma cells (Wehrle-Haller, 2003). POU3F2 may 
therefore modulate the properties of melanoma cells via autocrine KITL signalling.  
A second mechanism by which POU3F2 may enhance the motile and malignant properties 
of melanoma cells is through regulation of the cGMP-specific phosphodiesterase PDE5A. 
Arozarena et al (Arozarena et al., 2011) have shown that POU3F2 binds to two sites in the 
PDE5A proximal promoter upstream of the TSS to repress its expression. PDE5A down-
regulation has only a minor effect on proliferation, but potently increases melanoma cell 
invasion. Diminished PDE5A levels lead to an increase in cGMP and in cytosolic Ca2+, 
stimulating contractility and inducing invasion. In agreement with this idea, PDE5A levels 
are also down-regulated in human melanoma tumours. Hence, this model postulates that in 
melanoma cells, oncogenic BRAF promotes invasion through POU3F2-mediated repression 
of PDE5A. The ability of POU3F2 to act as a repressor at the PDE5A promoter is 
nevertheless surprising considering that it acts as a potent transcriptional activator in many 
other promoter contexts (Kobi et al., 2010).  
ii. MITF activates genes required for proliferation and represses genes involved in invasion. 
As described above, evidence from cell based models and human tumours suggest that 
MITF is a major regulator of melanoma cell proliferation. SiRNA-mediated silencing of 
MITF in proliferative melanoma cells leads to a rapid growth arrest confirming that it is 
indeed a critical regulator of proliferation (Carreira et al., 2006). Acute loss of MITF through 
siRNA mediated silencing has been reported to arrest cells at the G1/S phase transition 
through indirect regulation of CDKN1B (p27Kip1) via direct regulation of Diaphanous related 
formin DIAPH1. DIAPH1 promotes actin polymerization and coordinates the actin 
cytoskeleton and microtubule networks at the cell periphery (Carreira et al., 2006). MITF 
directly regulates DIAPH1 expression leading to reorganization of the actin cytoskeleton, 
accounting at least in part for the dramatic change in cell morphology seen upon MITF 
silencing, and increased ROCK-dependent invasiveness. MITF regulation of DIAPH1 also 
indirectly controls CDNK1B degradation leading to a G1 cell cycle arrest.  
While the above model accounts for many of the changes seen upon MITF silencing, it has 
been shown more recently that loss of MITF also leads to defects in mitosis and induces cell 
senescence (Giuliano et al., 2010; Strub et al., 2011). MITF silenced cells exhibit many 
characteristics of senescence such as enlarged and flattened cell morphology and 
senescence-associated β-galactosidase staining and heterochromatin foci.  Giuliano et al 
(Giuliano et al., 2010) showed that acute MITF silencing induced the DNA damage response 
leading to activation of ATM and CHK2 resulting in p53 phosphorylation and stabilization. 
SiRNA depletion and pharmacologic inhibition showed that the DNA-damage response is 
required for entry into senescence.  
How does MITF regulate both the proliferative and invasive properties of melanoma cells, 
and why does loss of MITF result in DNA damage? To answer these questions, Strub et al 
(Strub et al., 2011) used ChIP coupled to high throughput seqencing (ChIP-seq) to profile 
genomic MITF occupancy and RNA-seq following MITF silencing to identify MITF 
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regulated genes. As currently available antibodies do not efficiently ChIP MITF, 501Mel 
cells expressing 3HA-tagged MITF were used. ChIP-seq was perfomed not only for tagged 
MITF, but also for RNA polymerase II (Pol II) and trimethylation of lysine 4 of histone H3 
(H3K4me3), a covalent histone modification found at the 5’-end of transcribed genes 
(Ruthenburg et al., 2007).  An example of MITF occupancy of the highly expressed 
Tyrosinase locus is shown in Fig. 2, where at least 5 MITF-occupied sites can be detected 
both upstream and downstream of the TSS along with transcribing RNA Pol II. Overall, 
12139 MITF occupied loci were identified, 9447 of which could be annotated to more than 
5000 potential target genes.  
 
 
Fig. 2. Example of MITF-occupancy at the Tyrosinase locus. UCSC genome browser view of 
MITF and Pol II-occupancy and H3K4me3 at the TYR locus. The principal MITF occupied 
sites are indicated by arrows. TSS shows the engaged Pol II at the transcription start site, PS, 
enhanced Pol II occupany at an intronic pause site, and TTS, the transcription termination 
site downstream of the TYR polyadenylation site.  The data are adapted from the data set of 
Strub et al, (Strub et al., 2011). 
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To determine which of these potential targets are regulated by MITF in 501Mel cells, RNA-
seq was performed following MITF silencing identifying a large collection of both up and 
down-regulated genes (Strub et al., 2011). Amongst the genes that appear positively 
regulated by MITF are at least 31 genes involved in DNA replication, recombination and 
repair including LIG1 encoding DNA ligase 1, involved in the religation of Okazaki 
fragments during DNA replication, as well as religation during DNA repair and 
maintenance of genome stability (Bentley et al., 2002; Tomkinson and Mackey, 1998), and 
TERT (Telomerase reverse transcriptase) required for the proper replication of telomeres 
and frequently expressed in human tumours, (Artandi and DePinho, 2000; Artandi and 
DePinho, ; Kim et al., 1994; Rudolph et al., 1999). In addition, MITF regulates a set of 39 
genes involved in centromere organisation and mitosis including the G2-specific cyclins B1 
and F (CCNB1, CCNF) that promote entry into mitosis, as well as polo-like kinase 1 (PLK1) 
(Schmit et al., 2009), the CENPA-nucleosome associated and CENPA-nucleosome distal 
complexes and the chromosomal passenger complex. Consequently, siMITF silencing leads 
to mitotic defects with a high frequency of  binucleate and micronuclei containing cells.   
Together these results provide a more comprehensive picture of how MITF promotes 
proliferation by activating genes involved in DNA replication and repair as well as mitosis. 
Loss of expression of genes like LIG1 and TERT leads to incomplete DNA replication and 
telomere exposition activating the DNA damage and the senescence responses. We propose 
that, acute siMITF silencing in rapidly proliferating cells induces replication and mitotic 
defects too severe to be repaired and cells enter in senescence. However, the existence of 
senescent cells in human melanoma tumours has not yet been investigated and our results 
do not exclude the possibility that in vivo, decreased MITF expression could be offset by up-
regulation of other pathways that suppress senescence to produce slow-cycling invasive 
cells. Alternatively, a more gradual reduction of MITF expression such as may take place in 
tumours would allow cells to adapt progressively to slower growth due to diminished levels 
of replication and mitosis factors and not accumulate the high levels of DNA damage that 
trigger the senescence response.  
In contrast to the above, genomic profiling of MITF occupancy revealed genes that appear to 
be directly repressed by MITF. Amongst these are genes influencing metastasis such as 
MCAM (Ouhtit et al., 2009), SHC4 (Fagiani et al., 2007). Comparison of the ChIP-seq and 
mRNA-seq data shows the presence of at least 3 upstream and two intronic MITF occupied 
sites at the SHC4 locus and enhanced mRNA expression upon MITF knockdown (Figs. 3A 
and B). Increased SHC4 protein expression can also be seen upon MITF silencing (Fig 3C). 
SHC4 therefore appears to be directly repressed by MITF suggesting that MITF both 
activates and represses transcription in a promoter context-dependent manner similar to 
POU3F2 discussed above.  
SHC4 (also known as SHCD (Hawley et al., 2011), or RaLP, retinoic acid-like inducible like 
protein) belongs to the family of SRC homology and collagen (Shc) signal transduction 
adaptor proteins. These proteins share a common organisation with an N-terminal 
phosphotyrosine-binding (PTB) domain, a central region rich in proline and glycine residues 
(CH1) and a C-terminal SRC homologue 2 (SH2) domain (Pasini et al., 2009). A second N-
terminal collagen homology (CH2) region is present in the longest isoform of SHC4. SHC4 is 
of particular interest in melanoma as its expression is tightly correlated with tumour stage. 
SHC4 expression is low or undetectable in benign nevi and in early radial growth phase 
tumours, but is strongly expressed in the vertical growth phase and in metastases. SHC4 
functions as a substrate of activated IGF-1 and EGF receptors to enhance MAPK signaling 
and cell migration (Fagiani et al., 2007; Pasini et al., 2009). In contrast, SHC4 silencing in 
metastatic cells reduces their migration in vitro and inhibits tumour growth in vivo. 
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Fig. 3. MITF occupies sites at SHC4 locus and represses its expression. A. UCSC genome 
browser view of MITF occupancy and H3K4me3 at the SHC4 locus. The principal MITF 
occupied sites are indicated by arrows. B. UCSC genome browser view of mRNA-seq data 
from 501Mel cells treated with control Luciferase or MITF siRNAs.  Increased expression of 
the SHC4 gene can be clearly observed in the siMITF cells.  C. Immunoblot showing 
increased SHC4 protein expression in total extracts from 501Mel cells following MITF 
silencing with 20 or 50 nM of siRNA (lanes 2 and 3, respectively). ChIP- and mRNA-seq data 
are adapted from Strub et al, (Strub et al., 2011). 
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Together with the results of the ChIP- and RNA-seq, these observations suggest a novel 
MITF-SHC4 axis in the control of melanoma cell invasion. Proliferating cells express high 
levels of MITF that repress SHC4 expression, but the loss of MITF that takes place during 
phenotype switching de-represses SHC4 expression to promote migration and metastasis 
(summarised in Fig. 4).  
 
 
 
 
Fig. 4. Summary of regulatory interactions. in the POU3F2-MITF-SHC4 axis. As described in 
the main text, activated BRAF induces POU3F2 expression which in turn has been described 
to either activate or repress MITF expression. POU3F2 also activates KITL expression but 
represses PDE5A to promote motility and migration.  MITF activates a series of genes 
involved in DNA replication and repair, mitosis and critical cyclin genes, but represses 
expression of SHC4 and MCAM that promote invasion and metastasis.  
4. Future perspectives  
In this review, we have limited our discussion to the hypothesis that POU3F2, MITF and 
SHC4 form a regulatory axis that controls the proliferative and invasive properties of 
melanoma cells. These are of course not the only transcription factors that regulate the 
properties of melanoma cells.  For example, recent studies have shown that GLI2 and ATF2 
modulate the invasive properties of melanoma cells. GLI2 is a transcription factor normally 
associated with Sonic Hedgehog (SHH) signaling is present in melanoma cells where its 
expression is rather controlled by TGFbeta and SMAD signaling (Alexaki et al., 2010; 
Dennler et al., 2009; Santiago-Walker and Herlyn, 2010). GLI2 is overexpressed in 
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subpopulations of cells and these GLI2-high cells metastasise to bone more readily than 
GLI2-low cells. GLI2 appears to promote invasion and metastasis through suppression of E-
cadherin expression leading to a mesenchymal-like phenotype. Also, the transcription factor 
ATF2 has been shown to attenuate melanoma susceptibility to apoptosis and to promote its 
ability to form tumors in xenografts (Bhoumik and Ronai, 2008; Shah et al., 2011). In mouse 
melanoma models, expression of mutant ATF2 in melanocytes strongly attenuated tumour 
formation. ATF2 appears to modulate MITF expression through ATF2-JunB-dependent 
suppression of expression of SOX10 a factor that binds to and activates the MITF-M 
promoter. Morevover, on melanoma tissue microarrays, a high nuclear ATF2 to MITF ratio 
was associated with metastatic disease and poor prognosis. In the future it will important to 
develop more complex mouse melanoma models in which POU3F2 and/or MITF, GLI2 and 
ATF2 are (in)activated or mutated to study combinatorial control by multiple transcription 
factors in melanoma. This will be a challenging, but important task.    
We have discussed the proposition that the regulatory interactions between POU3F2-
MITF-SHC4 explain in part the phenotype switching of melanoma cells. However, one 
important and outstanding question concerns the signal(s) in the tumour 
microenvironment responsible for modulating the expression of POU3F2 and MITF. Are 
these diffusable signals emanating from cells within or outside the tumour or are cell-cell 
contacts between the tumour cells and the stroma or amongst tumour cells involved ? An 
alternative possibility is that phenotype switching may take place spontaneously through 
transient stochastic changes in the expression of POU3F2 or MITF in single cells that set 
up a reinforcing positive feedback loop to establish a novel stable state. For example, 
down-regulation of MITF leads to up-regulation of POU3F2 (Strub et al., 2011), but 
elevated levels of POU3F2 repress MITF. Given this situation, a transient reduction in 
MITF could set up a reinforcing loop of POU3F2-mediated MITF repression.  This would 
explain the spontaneous appearance of cells low-MITF expressing cells in in vitro cultures 
of otherwise high-MITF expressing cell types. It remains possible that in the tumour 
environment, extracellular signals may influence the expression of MITF or POU3F2, but 
the important point is that the effect of these signals can be amplified by the positive and 
negative feedback loops between these factors.  The role that stochastic changes in 
transcriptional ‘noise’ may play in biological processes is only just beginning to be 
considered (Kashyap et al., 2009; Leisner et al., 2008). Whatever the mechanism involved,  
key features of melanoma cells are their plasticity and heterogeneity. As discussed above, 
Cheli et al (Cheli et al., 2011) identified low-MITF expression as a criteria for selecting 
cells with enhanced tumour initiating properties. This fits with the previously proposed 
‘rheostat’ model of MITF expression where high levels of MITF drive a G1/S arrest and 
differentiation, while low levels are associated with slow cycling tumour initiating cells, 
and intermediate levels are optimum for proliferation (Carreira et al., 2006; Hoek and 
Goding, 2010).  
However, MITF is not the only biomarker that has been used to select slow cycling tumour 
initiating cells. Roesch et al., (Roesch et al., 2010) have used the JARID1B histone 
demethylase as a marker to identify a population of slow cycling cells within the tumour 
population. Similar to purified low-MITF cells, purified JARID1B-positive cells give rise to a 
highly proliferative progeny showing the dynamics of their expression. Moreover, JARID1B 
silencing promotes a transient acceleration of tumor growth that is followed by exhaustion. 
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This observation suggests that the continuous dynamic appearance of a JARID1B-positive 
subpopulation is essential to maintain tumor growth. There are thus a number of parallels 
between JARID1B and MITF expression both in terms of the dynamics of their expression 
and the properties they confer to tumour cells. Unfortunately, Roesch et al, did not 
specifically assess MITF expression in the slow cycling JARID1B-positive cells, that one 
would predict to have low MITF expression or at least low levels of ‘active’ MITF. Cheli et 
al, (Cheli et al., 2011) however,  did not observe a consistent increase in JARID1B expression 
in the MITF low population. Previousy other markers such as CD133 (Monzani et al., 2007) 
or ABCB5 (Schatton et al., 2008; Zabierowski and Herlyn, 2008), have been used to 
characterise stem-like subpopulations in melanomas. Does this mean that there are multiple 
distinct slow cycling tumour cell populations characterised by different transcriptional 
programmes? Future studies should answer these questions.  
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